BMY News and Press, Bristol-Myers Squibb Company From 06/28/24

2024-06-28 11:20:45 ET Summary SCHD is a high-quality dividend growth ETF that has lagged the market, making it more attractive on a relative basis. Over the last decade, SCHD grew its dividend by 124%, outpacing inflation and providing significant purchasing power gains. SCHD...

2024-06-28 10:22:38 ET Summary BMY stock has seen a rapid correction, but my analysis suggests it's a buy the dip opportunity. Read on. Despite challenges with patent expirations, BMY's product line and pipeline development show promise for future growth. With an implied P/E m...

2024-06-28 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-28 07:21:38 ET Summary Fragile stagflation presents challenges for investors, with limited opportunities for good returns in stocks and bonds. It is likely markets will experience a lost decade in real terms when measured from 2022. I share 5 stocks I recently sold, wh...

2024-06-27 06:56:19 ET More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk hypertensio...

2024-06-25 12:54:41 ET Summary AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with N...

2024-06-23 13:38:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Income-oriented investors love finding dividend stocks to buy now. That’s particularly true when those stocks are on sale, as many continue to be. However, heading into summer, many ...

2024-06-23 11:13:33 ET Summary Since the publication of my last article, Pfizer has continued to surprise me pleasantly. In early May, Pfizer published financial results for the first quarter of 2024, which were enthusiastically received by Wall Street. On June 14, 2024, the c...

2024-06-22 07:15:00 ET A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too. We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now. Here's why they pick...

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34% in pretreated patients with locally advanced or metastatic CRC harboring a KRAS G12C mutation 1 Second FDA approval for KRAZATI - r...